Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models

被引:7
|
作者
Siripuram, Vijay K. [1 ]
Wright, Daniel F. B. [1 ]
Barclay, Murray L. [2 ,3 ]
Duffull, Stephen B. [1 ]
机构
[1] Univ Otago, Sch Pharm, Otago Pharmacometr Grp, Dunedin, New Zealand
[2] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand
[3] Christchurch Hosp, Dept Clin Pharmacol, Christchurch, New Zealand
关键词
Identifiability; Parameter precision; Population analysis; PKPD models; Optimal study design; NONMEM; MIXED-EFFECTS MODELS; 4 BASIC MODELS; STRUCTURAL IDENTIFIABILITY; GLOBAL IDENTIFIABILITY; COMPARTMENTAL-MODELS; PARAMETER-ESTIMATION; DESIGN; RESPONSES; SYSTEMS; INDISTINGUISHABILITY;
D O I
10.1007/s10928-017-9530-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Identifiability is an important component of pharmacokinetic-pharmacodynamic (PKPD) model development. Structural identifiability is concerned with the uniqueness of the model parameters for a set of perfect input-output data and deterministic identifiability with the precision of parameter estimation given imperfect input-output data. We introduce two subcategories of deterministic identifiability, external and internal, and consider factors that distinguish between these forms. We define external deterministic identifiability as a function of externally controllable variables, i.e., the design, and internal deterministic identifiability as a function of the model and its parameter values. The concepts are explored using three common PK and PKPD models, and verified for their precision for the selected set of parameter values under optimal design.
引用
收藏
页码:415 / 423
页数:9
相关论文
共 50 条
  • [21] Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models
    Jen, J
    Laughlin, M
    Chung, C
    Heft, S
    Affrime, MB
    Gupta, SK
    Glue, P
    Hajian, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) : 349 - 361
  • [22] Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia
    Zoubir Djerada
    Catherine Feliu
    Yoann Cazaubon
    Faouzi Smati
    Philippe Gomis
    Dominique Guerrot
    Beny Charbit
    Olivier Fernandes
    Jean-Marc Malinovsky
    Clinical Pharmacokinetics, 2018, 57 : 1135 - 1147
  • [23] A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide
    Phillips, L
    Grasela, TH
    Agnew, JR
    Ludwig, EA
    Thompson, GA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 370 - 383
  • [24] Population pharmacokinetic-pharmacodynamic modeling of spinal anesthesia with ropivacaine
    Djerada, Z.
    Feliu, C.
    Cazaubon, Y.
    Smati, F.
    Gomis, P.
    Charbit, B.
    Fernandes, O.
    Malinovsky, J. M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 18 - 18
  • [25] A Population Pharmacokinetic-Pharmacodynamic Model for Allopurinol in Patients with Gout
    Wright, Daniel F. B.
    Duffull, Stephen B.
    Merriman, Tony R.
    Barclay, Murray L.
    Stamp, Lisa K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S33 - S33
  • [26] Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia
    Djerada, Zoubir
    Feliu, Catherine
    Cazaubon, Yoann
    Smati, Faouzi
    Gomis, Philippe
    Guerrot, Dominique
    Charbit, Beny
    Fernandes, Olivier
    Malinovsky, Jean-Marc
    CLINICAL PHARMACOKINETICS, 2018, 57 (09) : 1135 - 1147
  • [27] Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint
    Duffull, Stephen B.
    Wright, Daniel F. B.
    Winter, Helen R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (06) : 807 - 814
  • [28] Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments
    Andrew Hooker
    Paolo Vicini
    The AAPS Journal, 7
  • [29] Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments
    Dette, Holger
    Pepelyshev, Andrey
    Wong, Weng Kee
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (03) : 295 - 311
  • [30] Mefloquine pharmacokinetic-pharmacodynamic models: Implications for dosing and resistance
    Simpson, JA
    Watkins, ER
    Price, RN
    Aarons, L
    Kyle, DE
    White, NJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) : 3414 - 3424